This week, we will discuss the MYTEMP trial from Lancet. A cool idea, a cool cluster design. Warmly embraced by the Ontario dialysis community. But did it work?
New player in resistant hypertension?
This week we discussed aprocitentan, another endothelin receptor antagonist, this time being explored in the resistant hypertension arena - you know the #TenTweetNephJC drill, if you want a rapid catch up then here’s your place!
PRECISION Targeting in Resistant Hypertension
The PRECISION Visual Abstract
Is Aprocitentan effective in lowering BP in resistant hypertension? PRECISION trial answers it with a meticulous design. Checkout the VA by NSMC intern Sandhya Suresh which captures many elements of that meticulous design.
Another EMPA-Kidney Tweetorial
Friend of NephJC, Daniel Schwartz does a nice tweetorial on EMPA-Kidney
Don't Stop Me Now!
If you missed the latest NephJC discussion, at least read the highlights here.
You gotta know when to hold’em and know when to fold’em. Review the #TenTweetNephJC for the STOP ACEi Trial, and always hold onto your ACEi.
So where is the gift I was promised for donating to NephJC?
Use @CaptainChloride's tweetorial to prep for tonight's NephJC
TESTING 2.0 in Kidney Medicine
The NephJC editorial in Kidney Medicine is live. Great work from Anand Chellapan and Rachael Kermond, supported by Tiffany, Jade and Swap. Read it here.
With a bonus table which already needs updating post EMPAKIDNEY!
Keep Calm and Carry on Inhibiting the RAS
The STOP ACEi Trial - Visual Abstract
Does the discontinuation of RAS inhibitors improve eGFR in patients with advanced CKD? NSMC Intern Dana Larsen explains it graphically.
Nikhil has some thoughts on the Situation at Twitter
NephJC has moved newsletter hosts...again
Flozins strike again!
If you missed the biggest NephJC of the year, at least read the highlights here.
The future for refractory lupus nephritis?
Ten Tweet round up of exciting CAR T trial in patients with SLE discussed last month - check it out while you can!
